Subscribe to Newsletter

Content by Rob Coker:

Discovery & Development Drug Delivery

RIDE: A New Approach to CRISPR Delivery

| Rob Coker | 2 min read

A new study reports targeted CRISPR delivery in retinal and neurological disease models – without viral vectors.

Business & Regulation Standards & Regulation

AMF’s 2026 AMR Strategy, Revealed

| Rob Coker | 3 min read

The Access to Medicine Foundation has developed the 2026 AMR Benchmark to recognize and promote urgency in the ongoing AMR challenge.

Discovery & Development Drug Discovery

Breast Cancer Breakthrough

| Rob Coker

Scientists develop treatment that leads to complete regression of breast tumors in mice.

Discovery & Development Drug Discovery

Venom: The Last Advance

| Rob Coker | 2 min read

How snake venom, genomic data, and deep learning computation methods have combined to bring new advances in drug discovery.

Business & Regulation Standards & Regulation

Trump’s Tariffs

| Rob Coker | 3 min read

US-based pharmaceutical associations fear the supply chain repercussions of tariffs, and offer advice for a more sustainable alternative.

Business & Regulation Standards & Regulation

Settling the PrEP Patent Disputes

| Rob Coker | 2 min read

With US courts consistently ruling in favor of the PrEP drug manufacture, the CDC and DHHS have had no choice but to be humble.

Business & Regulation Standards & Regulation

Regulatory Flexibility in the Event of A Pandemic

| Rob Coker | 3 min read

Summarizing the updated lessons learned by the European Medicines Agency following the COVID-19 pandemic.

Manufacture Advanced Medicine

Pharma Fiction

| Rob Coker | 2 min read

A look back at The Medicine Maker archive and the influence of science fiction in the industry and science.

Manufacture Advanced Medicine

FDA or EMA Novel Drug Approvals 2024: Anagrams Edition

| Rob Coker

So you know your small molecule from your AAV, but can you unscramble the names of these 2024 novel drug approvals?

Business & Regulation Standards & Regulation

EFPIA Calls For Clarity Over JCA Concerns

| Rob Coker | 2 min read

EU-based associations voice concerns over joint clinical assessments and the lack of advice meetings.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register

May Issue of The Medicine Maker